title: Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review.
abstract: Patients with stage IV nasopharyngeal carcinoma (NPC) have a poor prognosis, even with effective chemotherapy. Target agents combined with chemotherapy may improve NPC patients' outcome. The case of a patient with NPC, who was treated by adding bevacizumab to chemotherapy after disease progression using first-line chemotherapy, is reported. Recently published literature about effects of combining bevacizumab with standard chemotherapy in NPC cell lines or patients are also reviewed and discussed. Consistent with a few preclinical trials and Phase II clinical trials, bevacizumab may reverse the drug resistance to chemotherapy, and its toxic side effects are well tolerated.
authors.affiliation: Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Wan
authors.initials: W
authors.lastname: He
authors.affiliation: Clinical Medical Research Center, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Chang
authors.initials: C
authors.lastname: Zou
authors.affiliation: Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Zhongkai
authors.initials: Z
authors.lastname: Tian
authors.affiliation: Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Wenyong
authors.initials: W
authors.lastname: Tan
authors.affiliation: Department of Oncology, Shenzhen Hospital of Southern Medical University, Shenzhen, China.
authors.forename: Weixi
authors.initials: W
authors.lastname: Shen
authors.affiliation: Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Jinghua
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Liping
authors.initials: L
authors.lastname: Liu
authors.affiliation: Department of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, China.
authors.forename: Ruilian
authors.initials: R
authors.lastname: Xu
keywords: bevacizumab; combination therapy; drug resistance; nasopharyngeal carcinoma